primari
target
sarscov
infect
epitheli
cell
respiratori
intestin
tract
angiotensinconvert
enzym
identifi
function
receptor
sarscov
shown
express
apic
domain
polar
cell
report
interferon
alfacon
examin
inhibitori
activ
sarscov
human
lung
carcinoma
epitheli
cell
line
three
african
green
monkey
kidney
epitheli
cell
line
interferon
alfacon
demonstr
signific
antivir
activ
neutral
red
uptak
assay
viru
yield
reduct
assay
data
might
provid
import
insight
mechan
pathogenesi
sarscov
allow
develop
antivir
therapi
treat
sar
infect
cov
infect
balbc
mice
data
support
use
ribavirin
treat
sar
patient
antibodi
sarscov
spike
protein
shown
block
entri
small
peptid
deriv
heptad
repeat
hr
region
sarscov
protein
shown
inhibit
sarscov
infect
interfer
sarscov
fusion
target
cell
sar
main
proteas
essenti
replic
cycl
sarscov
key
target
develop
antisar
drug
antisens
rna
rna
interfer
rnai
technolog
shown
potenti
prospect
treat
sever
diseas
consid
import
candid
medicin
treatment
sar
infect
howev
clear
evid
demonstr
support
clinic
observ
therefor
develop
new
antisarscov
agent
urgent
need
treatment
sar
patient
interferon
small
natur
synthet
protein
glycoprotein
cytokin
produc
leucocyt
tlymphocyt
fibroblast
respons
infect
biolog
stimuli
interferon
activ
tumorspecif
cytotox
tlymphocyt
play
import
role
destroy
foreign
cell
bodi
interferon
attach
special
receptor
surfac
cell
membran
induc
transcript
result
antivir
state
target
cell
research
discov
immun
system
produc
substanc
respons
viral
infect
act
antivir
agent
call
substanc
interferon
sinc
recombin
dna
technolog
provid
larger
suppli
interferon
allow
extens
research
regard
interferon
therapeut
properti
recent
studi
evalu
compound
approv
therapeut
use
human
vitro
inhibitor
sarscov
inhibit
mous
sarscov
replic
model
hybrid
interferon
interferon
alpha
ifnalpha
bd
mismatch
doublestrand
ds
rna
interferon
induc
ampligen
poli
poli
shown
potent
inhibit
viru
titer
lung
infect
mice
report
describ
cellbas
assay
use
sarscov
infect
human
lung
epitheli
cell
three
african
green
monkey
kidney
epitheli
cell
line
evalu
relat
compound
interferon
alfacon
ifnalfacon
consensu
interferon
sarscov
three
african
green
monkey
kidney
epitheli
cell
line
vero
vero
embryon
obtain
american
type
cultur
collect
atcc
manassa
va
vero
cell
routin
grown
minim
essenti
medium
mem
supplement
heatinactiv
fetal
bovin
serum
fb
hyclon
laboratori
logan
ut
vero
cell
maintain
mem
supplement
fb
mem
nonessenti
amino
acid
sigmaaldrich
co
st
loui
mo
mm
sodium
pyruv
sigmaaldrich
cell
human
lung
epitheli
cell
line
origin
human
pulmonari
adenocarcinoma
grown
dulbecco
modifi
eagl
minim
essenti
medium
dmem
supplement
fb
sarscov
strain
urbani
obtain
center
diseas
control
cdc
atlanta
ga
strain
propag
titrat
vero
cell
antivir
assay
serum
reduc
gentamicin
ad
medium
final
concentr
stock
solut
ifnalfacon
intermun
inc
brisban
ca
made
concentr
ml
store
ifnalfacon
solubil
mem
vitro
experi
neutral
red
nr
uptak
assay
determin
antivir
efficaci
compound
cytotox
use
vitro
evalu
cell
seed
tissu
cultur
plate
corn
incorpor
costa
ny
ml
cellsml
one
day
treat
ifnalfacon
differ
concentr
cell
infect
sarscov
isol
multipl
infect
moi
compound
viru
ad
equal
volum
ml
plate
incub
three
day
cell
viru
control
well
show
complet
viral
cytopath
effect
cpe
light
microscopi
concentr
compound
assay
inhibit
viral
cpe
triplic
cytotox
duplic
six
well
per
plate
set
asid
uninfect
untreat
cell
control
six
well
per
plate
receiv
viru
repres
control
viru
replic
three
day
post
viru
exposur
cell
score
percent
cpe
cytotox
microscop
observ
valu
obtain
convert
percent
untreat
uninfect
control
cell
cytotox
dose
cc
viru
inhibitori
dose
ic
repres
put
concentr
monolay
would
show
compound
cytotox
viru
cytopath
effect
respect
estim
regress
analysi
select
index
si
calcul
use
formula
si
cc
ic
activ
cpe
assay
verifi
spectrophotometr
nr
uptak
assay
plate
nr
assay
perform
use
modifi
method
cavenaugh
et
al
describ
barnard
et
al
briefli
nr
dye
ad
well
plate
plate
incub
approxim
h
dark
nr
solut
remov
well
rins
remain
dye
extract
use
ethanol
buffer
citrat
buffer
plate
read
nanomet
nm
wavelength
micropl
reader
opsi
dynex
technolog
chantilli
va
absorb
valu
express
percent
untreat
control
ic
cc
si
valu
calcul
describ
viru
yield
reduct
assay
sensit
assay
confirm
result
nr
uptak
assay
infecti
viru
yield
cpe
inhibit
assay
determin
supernat
test
well
previous
describ
sampl
well
compound
concentr
test
pool
titer
vero
cell
infecti
viru
cpe
assay
previous
describ
barnard
et
al
reduct
viru
yield
ic
calcul
linear
regress
analysi
repres
onelog
inhibit
titer
compar
untreat
viru
control
first
examin
effect
ifnalfacon
replic
sarscov
vero
cell
ifnalfacon
inhibit
viru
replic
dosedepend
manner
ifnalfacon
ic
ngml
cc
ngml
determin
nr
assay
tabl
howev
ifnalfacon
alway
work
vero
cell
activ
sarscov
vero
cell
sporad
appear
highli
variabl
depend
upon
condit
age
health
host
cell
monolay
vero
cell
rins
gentli
achiev
valid
nr
assay
ifnalfacon
inhibit
viru
replic
test
vero
cell
cell
ifnalfacon
provid
complet
protect
higher
dose
linear
dose
respons
lower
part
concentr
curv
ic
ngml
vero
cell
ngml
cell
respect
tabl
ifnalfacon
also
inhibit
sarscov
isol
si
valu
rang
tabl
cytopath
effect
infect
cell
observ
within
three
day
infect
activ
ifnalfacon
test
viru
yield
reduct
assay
ifnalfacon
reduc
viru
yield
ngml
vero
cell
ifnalfacon
reduc
viru
yield
ngml
vero
cell
ifnalfacon
ic
ngml
cell
confirm
activ
demonstr
nr
assay
tabl
sarscov
found
product
infect
human
bronchial
epitheli
cell
sarscovinduc
cpe
initi
observ
medium
contain
fc
day
fc
day
base
observ
ifnalfacon
evalu
test
inhibitori
effect
plate
sarscov
infect
cultur
fluid
infect
cell
supernat
kept
frozen
need
assess
infecti
viral
titer
standard
tcid
assay
permiss
vero
cell
describ
activ
ifnalfacon
confirm
viru
yield
reduct
assay
ifnalfacon
block
viral
product
incub
three
day
comparison
mocktreat
cell
reduc
viru
yield
ngml
tabl
ifnalfacon
inhibit
sarscov
infect
si
valu
tabl
also
verifi
sarscov
infect
human
bronchial
epitheli
cell
without
caus
signific
cytopath
effect
within
day
infect
tabl
interferon
consid
first
line
defens
viral
infect
interferon
type
divid
interferonalpha
leukocyt
interferon
produc
virusinfect
leukocyt
interferonbeta
fibroblast
interferon
produc
virusinfect
fibroblast
virusinfect
epitheli
cell
type
interferon
alphabeta
shown
effect
treat
patient
hepat
type
c
hcv
alpha
interferon
block
replic
sever
virus
also
activ
immun
system
also
shown
efficaci
treat
hairi
cell
leukemia
malign
melanoma
kaposi
sarcoma
aidsrel
cancer
interferon
alpha
shown
effect
inhibit
sarscov
replic
ifnalfacon
nonnatur
occur
novel
synthet
recombin
type
interferon
alpha
develop
compar
amino
acid
sequenc
sever
natur
interferonalpha
subtyp
assign
frequent
observ
amino
acid
correspond
posit
gener
consensu
molecul
ifnalfacon
also
approv
us
food
drug
administr
new
class
antihcv
inhibitor
ifnalfacon
ifn
test
human
trial
retreat
ifnalfacon
effect
therapi
patient
chronic
hepat
c
either
respond
previou
interferon
therapi
relaps
discontinu
interferon
therapi
paraga
et
al
report
ifnalfacon
antisarscov
activ
infect
cellbas
model
vitro
case
ifnalfacon
like
induc
antivir
state
target
cell
produc
cellular
environ
suitabl
viral
replic
howev
ifnalfacon
show
activ
cell
treat
ifnalfacon
infect
sarscov
suggest
ifnalfacon
might
directli
block
viral
replic
cell
alreadi
infect
loutfi
et
al
demonstr
ifnalfacon
combin
corticosteroid
preliminari
pilot
studi
assess
potenti
clinic
benefit
safeti
sar
patient
data
suggest
ifnalfacon
might
function
antivir
therapeut
treatment
sar
patient
epitheli
cell
primari
barrier
infect
microorgan
enter
host
via
bodi
caviti
epitheli
cell
organ
polar
fashion
two
distinct
membran
domain
apic
basolater
domain
primari
target
sarscov
infect
epitheli
cell
respiratori
intestin
tract
report
angiotensinconvert
enzym
function
receptor
sarscov
mossel
et
al
demonstr
vero
cell
express
human
apic
membranc
domain
infect
initi
success
apic
basolater
side
tseng
et
al
publish
first
sarscov
vitro
replic
model
use
monolay
polar
cell
receptor
sarscov
local
mediat
infect
apic
plasma
membran
respiratori
epitheli
cell
sarscov
entri
releas
may
focus
apic
surfac
cell
except
cell
human
respiratori
epitheli
cell
line
shown
yet
support
sarscov
infect
addit
search
vaccin
sarscov
import
advanc
knowledg
understand
sarscov
interact
polar
lung
epitheli
cell
look
approach
block
viral
replic
mean
chemotherapeut
control
develop
simpl
assay
system
screen
one
compound
cell
infect
sarscov
isol
viru
yield
reduct
assay
cell
treat
ifnalfacon
inocul
sarscov
isol
titer
infecti
viral
particl
supernat
harvest
infect
three
day
verifi
sarscov
propag
cell
day
tabl
human
lung
cell
line
provid
use
model
evalu
efficaci
mechan
antisar
compound
interferon
ifnalfacon
shown
activ
sarscov
test
human
lung
epitheli
cell
african
green
monkey
epitheli
cell
tabl
two
assay
system
ifnalfacon
demonstr
signific
antivir
activ
neutral
red
uptak
assay
viru
yield
reduct
assay
data
might
provid
us
import
insight
mechan
pathogenesi
sarscov
properti
might
therapeut
advantag
c
valu
express
mean
standard
deviat
